PT Jayamas Medica Industri Tbk (OMED) Fair Value & Analysis
Healthcare · ID · Market cap 5.1T IDR
Fair value as of: Jun 24, 2026
Analysis
PT Jayamas Medica Industri Tbk (OMED) currently trades at 212.00 IDR, while our model-based Fair Value estimate is 276.56 IDR — implying the stock looks roughly 30.5% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
PT Jayamas Medica Industri Tbk manufactures and sells medical devices in Indonesia, the United States of America, and South America. The company operates through three segments: Manufacturing, Distribution, and Retail. It offers medical disposables and consumables comprising medical gloves, syringes, masks, gauze, bandages, urine bag, foley catheter, alcoholic tissue, etc.; antiseptic and disinfectant fluids, povidone iodine, medical alcohol, Hdsol or blood cleansing liquid, etc.; and diagnostics and equipment, such as patient monitor, vital signs monitor, ECG reader, syringe pump, infusion pump, blood pressure monitors, oximeter, fingertip pulse oximeters etc. The company also provides walking aids and rehabilitation care products, including wheelchairs, crutches, walkers, arm slings etc.; biotechnology and laboratory products, such as pregnancy test, PCR test, blood collection tube, PCT tube, chemical reagents, etc; and hospital furniture products comprising patient bed, bed side …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PT Jayamas Medica Industri Tbk (OMED) undervalued?
What is the fair value of OMED?
What is the quality score of OMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.